That was the so-called DSNM-70 study in which, again, a quadruple therapy was compared to a triple therapy and, as already shown for other quadruple combinations, the addition in this case of elotuzumab to KRd – KRd was given as three cycles before stem cell collections, three cycles after stem cell collections and four cycles following transplant. After the induction treatments, so six cycles of either elo-KRd versus six cycles of KRd, there was clearly a higher rate of very good partial remission or better and also a significantly improved MRD-negativity in favor of the quadruple combination...
That was the so-called DSNM-70 study in which, again, a quadruple therapy was compared to a triple therapy and, as already shown for other quadruple combinations, the addition in this case of elotuzumab to KRd – KRd was given as three cycles before stem cell collections, three cycles after stem cell collections and four cycles following transplant. After the induction treatments, so six cycles of either elo-KRd versus six cycles of KRd, there was clearly a higher rate of very good partial remission or better and also a significantly improved MRD-negativity in favor of the quadruple combination. So, I think that we now also have, for the combination elo-KRd, the information that the addition of a monoclonal antibody to a triplet regimen improves at least the response, quality and MRD-negativity following induction therapy.